Post-effective amendment to a registration statement that is not immediately effective upon filing

Equity - Additional Information (Details)

v3.22.1
Equity - Additional Information (Details)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Oct. 15, 2021
shares
Jul. 27, 2021
USD ($)
shares
May 24, 2021
shares
May 23, 2021
Mar. 28, 2021
USD ($)
$ / shares
shares
Oct. 23, 2020
USD ($)
$ / shares
shares
Jul. 15, 2020
USD ($)
$ / shares
shares
Jul. 06, 2020
USD ($)
$ / shares
shares
Sep. 30, 2021
shares
Dec. 31, 2021
USD ($)
D
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Jul. 23, 2021
shares
Mar. 31, 2020
shares
Stockholders Equity [Line Items]                          
Common stock, shares authorized                   500,000,000 500,000,000    
Common stock, par value | $ / shares                   $ 0.001 $ 0.001    
Issuance of common stock for exercise of warrants and Unit Purchase Options (in shares)                   3,830,586      
Number of shares issued upon exercise of warrants   1,833,596               516,025      
Issuance of common stock for exercise of warrants and Unit Purchase Options | $                   $ 16,699      
Contingently issuable Earnout Shares Excluded from EPS computation                 185,472        
Common stock issued for consulting services (in shares)                   4,834,045      
Non-cash consulting expense | $                   $ 53,837      
Common stock issued | $                   $ 9,624 $ 2,579    
Loss on conversion of convertible notes payable | $                     $ 307    
Common stock issued to settle note conversion (in shares)                     1,138,199    
Awarded to employees as bonus for services provided                   200,000      
Compensation expenses | $                   $ 7,785 $ 730    
Common shares issued                     30,020    
Debt conversion, converted instrument, amount | $                     $ 100    
Debt conversion, original debt, amount | $                     $ 100    
Loss on settlement of accounts payable | $                   $ (121)      
Preferred stock, shares authorized                   50,000,000 50,000,000    
Preferred stock, shares issued                   0 0    
Preferred stock, par value | $ / shares                   $ 0.001 $ 0.001    
Number of shares outstanding                   0 0    
Warrant issued                   6,193,449      
Warrant, exercise price per share | $ / shares                   $ 9.09 $ 1.09    
Proceeds from exercise of warrant | $   $ 9,200               $ 16,699      
Net impact to additional paid-in capital | $                   $ 60,852      
Number of outstanding warrants                   9,305,790 3,075,470    
Change in fair value of the warrants | $                   $ (1,692)      
Number of units outstanding                   600,000   600,000  
Price per unit | $ / shares                   $ 10.00      
Aggregate exercise price | $                   $ 6,000      
Number of shares per right                   1      
Fractional shares issued upon conversion of rights                   0      
Unamortized compensation costs | $                   $ 31,100      
Common stock issued to settle accounts payable | $                     $ 145    
Loss on common stock issued to settle accounts payable | $                     42    
Substitute Warrants                          
Stockholders Equity [Line Items]                          
Deemed dividend - Earnout Shares | $                   2,700      
Net impact to additional paid-in capital | $                   0      
Additional deemed dividend recognized in the event of earnout shares milestone | $                   24,400      
Additional deemed dividend recognized in the event of earnout cash milestone | $                   $ 3,100      
Public Warrants                          
Stockholders Equity [Line Items]                          
Warrant, exercise price per share | $ / shares                   $ 11.50      
Warrants exercised                   1,144      
Number of outstanding warrants                   3,450,000      
Number of shares per warrant                   1      
Warrants expiration term                   5 years      
Redemption price per warrant (in dollars per share) | $ / shares                   $ 0.01      
Minimum threshold written notice period for redemption of warrants                   30 days      
Stock price trigger for redemption of warrants (in dollars per share) | $ / shares                   $ 21.00      
Threshold trading days for redemption of warrants | D                   20      
Redemption period | D                   30      
Public Warrants | Maximum                          
Stockholders Equity [Line Items]                          
Gross proceeds from exercise of warrants | $                   $ 100      
Placement Warrants                          
Stockholders Equity [Line Items]                          
Number of outstanding warrants                   136,250      
Change in fair value of the warrants | $                   $ 1,700 0    
Public Right                          
Stockholders Equity [Line Items]                          
Number of outstanding warrants                   6,900,000      
Placement Rights                          
Stockholders Equity [Line Items]                          
Number of outstanding warrants                   272,500      
GEM Warrant                          
Stockholders Equity [Line Items]                          
Contingently issuable Earnout Shares Excluded from EPS computation                   1,044,453      
Merger agreement                          
Stockholders Equity [Line Items]                          
Merger and PIPE Financing shares - common stock                   3,729,730      
Exchange Ratio     3.16                    
Merger agreement | Stockholders of NeuroRx                          
Stockholders Equity [Line Items]                          
Exchange Ratio     3.16 4.96                  
VaccineCo                          
Stockholders Equity [Line Items]                          
Merger and PIPE Financing shares - common stock 4,000,000                        
Common stock Warrants                          
Stockholders Equity [Line Items]                          
Warrant issued           139,645 279,291 4,000          
Warrant, exercise price per share | $ / shares           $ 15.25 $ 15.25 $ 15.25          
Warrant expiry date           Oct. 22, 2025 Jul. 14, 2025 Jul. 05, 2023          
Fair value on the date of issuance | $           $ 2,700 $ 2,700 $ 100          
Warrant, fair valued price per share | $ / shares           $ 9.64 $ 9.63 $ 7.63          
Common stock Warrants | Legacy NeuroRx Warrants                          
Stockholders Equity [Line Items]                          
Warrant issued         3,329,812                
Warrant, exercise price per share | $ / shares         $ 3.19                
Warrant expiry date         Mar. 27, 2024                
Fair value on the date of issuance | $         $ 60,900                
Warrants exercised   1,833,596     1,496,216                
Gross proceeds from exercise of warrants | $   $ 9,200     $ 7,500                
Substitute Warrants                          
Stockholders Equity [Line Items]                          
Warrant, exercise price per share | $ / shares                   $ 2.45      
Warrants exercised                   4,909,066      
Incremental compensation on modification | $                   $ 2,300      
Unamortized compensation costs | $                   23,800      
General and Administrative Expense [Member]                          
Stockholders Equity [Line Items]                          
Non-cash consulting expense | $                   53,800      
Compensation expenses | $                   $ 6,500 332    
Loss on settlement of accounts payable | $                     $ 100    
Common Stock                          
Stockholders Equity [Line Items]                          
Merger and PIPE Financing shares - common stock                   3,642,727 556,043    
Issuance of common stock for exercise of warrants and Unit Purchase Options (in shares)                   3,830,586      
Proceeds from issuance of common stock | $                   $ 37,000 $ 2,600    
Common Stock | General and Administrative Expense [Member]                          
Stockholders Equity [Line Items]                          
Compensation expenses | $                   $ 4,800      
Legacy NeuroRx Preferred Stock                          
Stockholders Equity [Line Items]                          
Preferred stock, par value | $ / shares                   $ 0.001 $ 0.001    
Legacy NeuroRx Preferred Stock | Convertible Series A Preferred Stock [Member]                          
Stockholders Equity [Line Items]                          
Preferred stock, shares authorized                   1,000,000 1,000,000    
Preferred stock, shares issued                   1,000,000 1,000,000    
Preferred stock, conversion basis                   one share of common stock for each preferred share      
Convertible preferred stock, liquidation preference per share | $ / shares                   $ 1.00 $ 1.00    
Number of shares outstanding     2,367,543                    
Shares issued upon conversion     7,480,836                    
Legacy NeuroRx Preferred Stock | Convertible Series B-1 Preferred Stock [Member]                          
Stockholders Equity [Line Items]                          
Preferred stock, shares authorized                   1,050,695 1,050,695    
Preferred stock, shares issued                   1,050,695 1,050,695    
Convertible preferred stock, liquidation preference per share | $ / shares                   $ 7.58 $ 7.58    
Legacy NeuroRx Preferred Stock | Convertible Series B-1A Preferred Stock [Member]                          
Stockholders Equity [Line Items]                          
Preferred stock, shares authorized                   316,848 316,848    
Preferred stock, shares issued                   316,848 316,848    
Convertible preferred stock, liquidation preference per share | $ / shares                   $ 6.82 $ 6.82    
Legacy NeuroRx Preferred Stock | Convertible Series B-2 Preferred Stock [Member]                          
Stockholders Equity [Line Items]                          
Preferred stock, shares authorized                     100,000    
Preferred stock, shares issued                         4,167
Preferred stock, par value | $ / shares                     $ 0.001    
Preferred stock, conversion basis                     one share of common stock for each share of  B-2 Preferred Stock    
Convertible preferred stock, liquidation preference per share | $ / shares                     $ 12.00    
Number of shares outstanding     4,167                    
Shares issued upon conversion     13,168